Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granulocyte-macrophage colony stimulating factor biosimilar - North China Pharmaceutical Corporation

Next Previous
Search
Drug Profile

Granulocyte-macrophage colony stimulating factor biosimilar - North China Pharmaceutical Corporation

Alternative Names: HUABEI JIMUXIN; Jimuxin; rhGM-CSF - North China Pharmaceutical Corporation

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator North China Pharmaceutical Corporation
  • Developer North China Pharmaceutical Corporation; Peking Union Medical College Hospital
  • Class Adjuvants; Glycoproteins; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Leucopenia
  • Phase II Pulmonary alveolar proteinosis

Most Recent Events

  • 30 Dec 2016 Granulocyte-macrophage colony stimulating factor biosimilar is still in phase II trials for Pulmonary alveolar proteinosis in China (Inhalation)
  • 26 Sep 2014 Launched prior to this date for Leucopenia (Chemotherapy-induced) in China (SC)
  • 26 Sep 2014 Launched prior to this date for Leucopenia (Radiotherapy-induced) in China (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top